Katharine K. Duncan
Scripps Research Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Katharine K. Duncan.
Journal of Medicinal Chemistry | 2013
Kristin D. Schleicher; Yoshikazu Sasaki; Annie Tam; Daisuke Kato; Katharine K. Duncan; Dale L. Boger
The total synthesis of a systematic series of vinblastine analogues that contain deep-seated structural modifications to the core ring system of the lower vindoline subunit is described. Complementary to the vindoline 6,5 DE ring system, compounds with 5,5, 6,6, and the reversed 5,6 membered DE ring systems were prepared. Both the natural cis and unnatural trans 6,6-membered ring systems proved accessible, with the latter representing a surprisingly effective class for analogue design. Following Fe(III)-promoted coupling with catharanthine and in situ oxidation to provide the corresponding vinblastine analogues, their evaluation provided unanticipated insights into how the structure of the vindoline subunit contributes to activity. Two potent analogues (81 and 44) possessing two different unprecedented modifications to the vindoline subunit core architecture were discovered that matched the potency of the comparison natural products and both lack the 6,7-double bond whose removal in vinblastine leads to a 100-fold drop in activity.
Journal of Medicinal Chemistry | 2012
Amanda L. Wolfe; Katharine K. Duncan; Nikhil K. Parelkar; Scott Weir; George Vielhauer; Dale L. Boger
A unique heterocyclic carbamate prodrug of seco-CBI-indole(2) that releases no residual byproduct is reported as a new member of a class of hydrolyzable prodrugs of the duocarmycin and CC-1065 family of natural products. The prodrug was designed to be activated by hydrolysis of a carbamate releasing the free drug without the cleavage release of a traceable extraneous group. Unlike prior carbamate prodrugs examined that are rapidly cleaved in vivo, the cyclic carbamate was found to be exceptionally stable to hydrolysis under both chemical and biological conditions providing a slow, sustained release of the exceptionally potent free drug. An in vivo evaluation of the prodrug found that its efficacy exceeded that of the parent drug, that its therapeutic window of efficacy versus toxicity is much larger than the parent drug, and that its slow free drug release permitted the safe and efficacious use of doses 150-fold higher than the parent compound.
Organic Letters | 2013
Erica L. Campbell; Colin K. Skepper; Kuppusamy Sankar; Katharine K. Duncan; Dale L. Boger
A powerful tandem [4 + 2]/[3 + 2] cycloaddition cascade of 1,3,4-oxadiazoles initiated by a transannular [4 + 2] cycloaddition is detailed. An impressive four rings, four carbon-carbon bonds, and six stereocenters are set on each site of the newly formed central six-membered ring in a cascade thermal reaction that proceeds at temperatures as low as 80 °C. The resulting cycloadducts provide the basis for the synthesis of unique analogues of vinblastine containing metabolically benign deep-seated cyclic modifications at the C3/C4 centers of the vindoline-derived subunit of the natural product.
Journal of Medicinal Chemistry | 2013
Amanda L. Wolfe; Katharine K. Duncan; Nikhil K. Parelkar; Douglas Brown; George Vielhauer; Dale L. Boger
Two novel cyclic N-acyl O-amino phenol prodrugs are reported as new members of a unique class of reductively cleaved prodrugs of the duocarmycin family of natural products. These prodrugs were explored with the expectation that they may be cleaved selectively within hypoxic tumor environments that have intrinsically higher concentrations of reducing nucleophiles and were designed to liberate the free drug without the release of an extraneous group. In vivo evaluation of the prodrug 6 showed that it exhibits extraordinary efficacy (T/C > 1500, L1210; 6/10 one year survivors), substantially exceeding that of the free drug, that its therapeutic window of activity is much larger, permitting a dosing ≥ 40-fold higher than the free drug, and yet that it displays a potency in vivo that approaches the free drug (within 3-fold). Clearly, the prodrug 6 benefits from either its controlled slow release of the free drug or its preferential intracellular reductive cleavage.
Bioorganic & Medicinal Chemistry | 2014
Katharine K. Duncan; Katerina Otrubova; Dale L. Boger
A series of α-ketooxazoles containing heteroatoms embedded within conformational constraints in the C2 acyl side chain of 2 (OL-135) were synthesized and evaluated as inhibitors of fatty acid amide hydrolase (FAAH). The studies reveal that the installation of a heteroatom (O) in the conformational constraint is achievable, although the potency of these novel derivatives is reduced slightly relative to 2 and the analogous 1,2,3,4-tetrahydronaphthalene series. Interestingly, both enantiomers (R and S) of the candidate inhibitors bearing a chiral center adjacent to the electrophilic carbonyl were found to effectively inhibit FAAH.
Organic Letters | 2012
Erick K. Leggans; Timothy J. Barker; Katharine K. Duncan; Dale L. Boger
Journal of Medicinal Chemistry | 2013
Erick K. Leggans; Katharine K. Duncan; Timothy J. Barker; Kristin D. Schleicher; Dale L. Boger
ACS Medicinal Chemistry Letters | 2011
Hiroaki Gotoh; Katharine K. Duncan; William M. Robertson; Dale L. Boger
ACS Medicinal Chemistry Letters | 2013
Timothy J. Barker; Katharine K. Duncan; Katerina Otrubova; Dale L. Boger
Journal of Medicinal Chemistry | 2013
Amanda L. Wolfe; Katharine K. Duncan; James P. Lajiness; Kaicheng Zhu; Adam S. Duerfeldt; Dale L. Boger